Scholar Rock Holding Corporation

About Scholar Rock Holding Corporation

Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines targeting the latent transforming growth factor-beta (TGFβ) superfamily. The company leverages its proprietary platform to selectively modulate growth factors implicated in disease pathways, advancing therapies for neuromuscular, fibrotic, and other serious conditions. Its lead product candidate, apitegromab, is in Phase 3 trials for spinal muscular atrophy (SMA).